Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Pancreatic cancer research

Silexion Therapeutics Corp. (NASDAQ:SLXN) stock is trading higher on Thursday, with a session volume of 16.87 million compared to the average volume of 74.2 thousand as per data from Benzinga Pro.

The company released new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of pancreatic cancer metastasis and shows anti-tumor activity.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.